•

 03/14/08 Inspire Announces Poster Presentations at 2008 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

•

 11/28/07 Inspire Initiates Phase 3 Trial of Epinastine Nasal Spray for Allergic Rhinitis

•

 09/09/07 Inspire Announces Oral Presentation of Phase 2 Epinastine Nasal Spray Data at American College of Allergy, Asthma & Immunology Meeting

•

 08/13/07 Inspire Pharmaceuticals Launches AzaSite™ in the United States for Ocular Infections

•

 07/11/07 Inspire to Advance Epinastine Nasal Spray to Phase 3

•

 04/27/07 Inspire Announces FDA Approval Of AzaSite™
• 02/16/07 Inspire Licenses AzaSite™ for Ocular Infections
• 08/07/06 Inspire Announces Vice President Appointments
• 04/19/06 Inspire Announces Receipt of Milestone Payment from Japanese Dry Eye Partner
• 02/21/06

Inspire Announces Development and License Agreement with Boehringer Ingelheim International for Intranasal Epinastine in the United States and Canada

• 11/15/04

Inspire Senior Vice President Receives Industrial Innovation Award for Product Advancements with P2Y2 Receptors
• 11/04/04

Inspire Pharmaceuticals Licenses Novel Glaucoma Technology; Addition of New Ophthalmic Program Enhances Pipeline
• 12/08/03

Allergan and Inspire Enter into Collaboration to Co-Promote Elestat™ in the U.S.
• 10/04/02

Inspire Pharmaceuticals Announces Collaboration With Cystic Fibrosis Foundation Therapeutics
• 06/27/01 Allergan and Inspire Enter into a Collaboration for the Development of Two Novel Compounds for the Treatment of Dry Eye


 

 

 

 

Page last updated: 27-Mar-2008
Copyright © 1999-2005 Inspire Pharmaceuticals Inc. All rights reserved